Anti-CCP: History and its usefulness

Clinical and Developmental Immunology

Volumn 12, Issue 2, 2005, Pages 131-135

  Herold, M ^a   Boeser, V ^a   Russe, E ^a   Klotz, W ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Anti CCP; Automated determination; Enzyme linked immunosorbent assays; Rheumatoid arthritis

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE ANTIBODY; AUTOANTIBODY; CYCLIC CITRULLINATED PEPTIDE; CYCLOPEPTIDE; DIAGNOSTIC AGENT;

ANTIBODY DETECTION; ARTICLE; AUTOANALYSIS; BLOOD SAMPLING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOASSAY; INTERMETHOD COMPARISON; LABORATORY TEST; MALE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; ANTIBODY SPECIFICITY; IMMUNOLOGY; RHEUMATOID ARTHRITIS; UTILIZATION REVIEW;

ANTIBODY SPECIFICITY; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; PEPTIDES, CYCLIC; SENSITIVITY AND SPECIFICITY;

EID: 24744469463     PISSN: 17402522     EISSN: None     Source Type: Journal    
DOI: 10.1080/14767050500134217     Document Type: Article

References (45)

1. Aho K, Palosuo T, Lukka M, Kurki P, Isomaki H, Kautiainen H, von Essen R. 1999. Anti-filaggrin antibodies in recent-onset arthritis. Scand J Rheumatol 28:113-116.
2. Araki C, Hayashi N, Moriyama M, Morinobu S, Mukai M, Koshiba M, Kawano S, Kumagai S. 2004. Usefulness of anti-cyclic citrullinated peptide antibodies (anti-CCP) for the diagnosis of rheumatoid arthritis. Rinsho Byori 52:966-972.
3. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al. 1988. The American Rheumatism Association 1987 revised Criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315-324.
4. Bas S, Perneger TV, Seitz M, Tiercy JM, Roux-Lombard P, Guerne PA. 2002. Diagnostic tests for rheumatoid arthritis: Comparison of anti-cyclic citrullinated peptide antibodies, anti-keratin antibodies and IgM rheumatoid factors. Rheumatology 41:809-814.
5. Bas S, Genevay S, Meyer O, Gabay C. 2003. Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis. Rheumatology 42:677-680.
6. Berglin E, Padyukov L, Sundin U, Hallmans G, Stenlund H, Van Venrooij WJ, Klareskog L, Dahlqvist SR. 2004. A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritis. Arthritis Res Ther 6:R303-R308, Epub 2004 May 11.
7. Bizzaro N, Mazzanti G, Tonutti E, Villalta D, Tozzoli R. 2001. Diagnostic accuracy of the anti-citrulline antibody assay for rheumatoid arthritis. Clin Chem 47:1089-1093.
8. Boekel MAM, Vossenaar ER, van den Hoogen FHJ, van Venrooij WJ. 2002. Autoantibody systems in rheumatoid arthritis: Specificity, sensitivity and diagnostic value. Arthritis Res 4:87-93.
9. Dubucquoi S, Solau-Gervais E, Lefranc D, Marguerie L, Sibilia J, Goetz J, Dutoit V, Fauchais AL, Hachulla E, Flipo RM, Prin L. 2004. Evaluation of anti-citrullinated filaggrin antibodies as hallmarks for the diagnosis of rheumatic diseases. Ann Rheum Dis 63:415-419.
10. Forslind K, Ahlmen M, Eberhardt K, Hafstrom I, Svensson B, BARFOT Study Group. 2004. Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: Role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis 63:1090-1095.
11. van Gaalen FA, van Aken J, Huizinga TW, Schreuder GM, Breedveld FC, Zanelli E, van Venrooij WJ, Verweij CL, Toes RE, de Vries RR. 2004a. Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis. Arthritis Rheum 50:2113-2121.
12. van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, de Jong BA, Breedveld FC, Verweij CL, Toes RE, Huizinga TW. 2004b. Autoantibodies to cyclic citrullinated peptides (CCP) predict progression to rheumatoid arthritis in patients with undifferentiated arthritis. Arthritis Rheum 50:709-715.
13. Garcia-Berrocal B, Gonzalez C, Perez M, Navajo JA, Moreta I, Davila C, Gonzalez-Buitrago JM. 2005. Anti-cyclic citrullinated peptide autoantibodies in IgM rheumatoid factor-positive patients. Clin Chim Acta 354:123-130.
14. Girelli F, Foschi FG, Bedeschi E, Calderoni V, Stefanini GF, Martinelli MG. 2004. Is anti cyclic citrullinated peptide a useful laboratory test for the diagnosis of rheumatoid arthritis? Allerg Immunol 36:127-130.
15. Goldbach-Mansky R, Lee J, McCoy A, Hoxworth J, Yarboro C, Smolen JS, Steiner G, Rosen A, Zhang C, Menard HA, Zhou ZJ, Palosuo T, Van Venrooij WJ, Wilder RL, Klippel JH, Schumacher Jr, HR, El-Gabalawy HS. 2000. Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res 2:236-243.
16. Hoet RM, van Venrooij WJ. 1992. The perinuclear factor and antikeratin antibodies in rheumatoid arthritis. In: Smolen J, Kalden J, Maini RN, editors. Rheumatoid arthritis. Berlin: Springer Verlag, pp 299-318.
17. Hoet RM, Boerbooms AM, Arends M, et al. 1991. Antiperinuclear, a marker autoantibody for rheumatoid arthritis: Colocalisation of the perinuclear factor and profilagrin. Ann Rheum Dis 50:611-618.
18. Jansen AL, van der Horst-Bruinsma I, van Schaardenburg D, van de Stadt RJ, de Koning MH, Dijkmans BA. 2002. Rheumatoid factor and antibodies to cyclic citrullinated peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients with early arthritis. J Rheumatol 29:2034-2040.
19. Kastbom A, Strandberg G, Lindroos A, Skogh T. 2004. Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Ann Rheum Dis 63:1085-1089.
20. Kroot EJ, de Jong BA, van Leeuwen MA, Swinkels H, van den Hoogen FH, van't Hof M, van de Putte LB, van Rijswijk MH, van Venrooij WJ, van Riel PL. 2000. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 43:1831-1835.
21. Kurki P, Aho K, Palosuo T, Heliövaara M. 1992. Immunopathology of rheumatoid arthritis. Antikeratin antibodies precede the clinical disease. Arthritis Rheum 35:914-917.
22. Lawrence RC, Helmick CG, Arnett FC, et al. 1998. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 41:778-799.
23. Lee DM, Schur PH. 2003. Clinical utility of the anti-CCP assay in patients with rheumatic diseases. Ann Rheum Dis 62:870-874.
24. Lindqvist E, Eberhardt K, Bendtzen K, Heinegard D, Saxne T. 2005. Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis 64:196-201.
25. Lopez-Hoyos M, Ruiz de Alegria C, Blanco R, Crespo J, Pena M, Rodriguez-Valverde V, Martinez-Taboada VM. 2004. Clinical utility of anti-CCP antibodies in the differential diagnosis of elderly-onset rheumatoid arthritis and polymyalgia rheumatica. Rheumatology 43:655-657.
26. Maddali Bongi S, Manetti R, Melchiorre D, Turchini S, Boccaccini P, Vanni L, Maggi E. 2004. Anti-cyclic citrullinated peptide antibodies are highly associated with severe bone lesions in rheumatoid arthritis anti-CCP and bone damage in RA. Autoimmunity 37:495-501.
27. Meyer O, Labarre C, Dougados M, Goupille P, Cantagrel A, Dubois A, Nicaise-Roland P, Sibilia J, Combe B. 2003. Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis 62:120-126.
28. Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MH, Habibuw MR, Vandenbroucke JP, Dijkmans BA. 2004. Specific autoantibodies precede the symptoms of rheumatoid arthritis: A study of serial measurements in blood donors. Arthritis Rheum 50:380-386.
29. Nielen MM, van der Horst AR, van Schaardenburg D, van der Horst-Bruinsma IE, van de Stadt RJ, Aarden L, Dijkmans BA, Hamann D. 2005. Antibodies to citrullinated human fibrinogen (ACF) have diagnostic and prognostic value in early arthritis. Ann Rheum Dis Jan 7 [Epub ahead of print].
30. Nienhuis RLF, Mandema EA. 1964. A new serum factor in patients with rheumatoid arthritis. The perinuclear factor. Ann Rheum Dis 23:302-305.
31. Rantapaa-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H, Sundin U, van Venrooij WJ. 2003. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 48:2741-2749.
32. Raza K, Breese M, Nightingale P, Kumar K, Potter T, Carruthers DM, Situnayake D, Gordon C, Buckley CD, Salmon M, Kitas GD. 2005. Predictive value of antibodies to cyclic citrullinated peptide in patients with very early inflammatory arthritis. J Rheumatol 32:231-238.
33. Saraux A, Berthelot JM, Devauchelle V, Bendaoud B, Chales G, Le Henaff C, Thorel JB, Hoang S, Jousse S, Baron D, Le Goff P, Youinou P. 2003. Value of antibodies to citrulline-containing peptides for diagnosing early rheumatoid arthritis. J Rheumatol 30:2535-2539.
34. Schellekens GA, de Jong BAW, van den Hoogen FHJ, van de Putte LBA. 1998. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Investig 101:273-281.
35. Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC, van Venrooij WJ. 2000. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 43:155-163.
36. Sebbag M, Simon M, Vincent C, Masson-Bessiere C, Girbal E, Durieux JJ, Serre G. 1995. The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies. J Clin Investig 95:2672-2679.
37. Suzuki K, Sawada T, Murakami A, Matsui T, Tohma S, Nakazono K, Takemura M, Takasaki Y, Mimori T, Yamamoto K. 2003. High diagnostic performance of ELISA detection of antibodies to citrullinated antigens in rheumatoid arthritis. Scand J Rheumatol 32:197-204.
38. Vallbracht I, Rieber J, Oppermann M, Forger F, Siebert U, Helmke K. 2004. Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis. Ann Rheum Dis 63:1079-1084.
39. Vasishta A. 2002. Diagnosing early-onset rheumatoid arthritis: The role of anti-CCP antibodies. Am Clin Lab 21:34-36.
40. Vencovsky J, Machacek S, Sedova L, Kafkova J, Gatterova J, Pesakova V, Ruzickova S. 2003. Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. Ann Rheum Dis 62:427-430.
41. van Venrooij WJ, Vossenaar ER, Zendman AJ. 2004. Anti-CCP antibodies: The new rheumatoid factor in the serology of rheumatoid arthritis. Autoimmun Rev 3(Suppl 1):S17-S19.
42. Vincent C, Simon M, Sebbag M, Girbal-Neuhauser E, Durieux JJ, Cantagrel A, Fournie B, Mazieres B, Serre G. 1998. Immunoblotting detection of autoantibodies to human epidermis filaggrin: A new diagnostic test for rheumatoid arthritis. J Rheumatol 25:838-846.
43. Vossenaar ER, Venrooij WJ. 2004. Anti-CCP antibodies, a specific marker for (early) rheumatoid arthritis. Clin Appl Immunol Rev 4:239-262.
44. Young BVJJ, Mallaya RK, Leslie RDG, Clark CJM, Hamblin TJ. 1979. Antikeratin antibodies in rheumatoid arthritis. Br Med J 2:97-99.
45. Zeng X, Ai M, Tian X, Gan X, Shi Y, Song Q, Tang F. 2003. Diagnostic value of anti-cyclic citrullinated peptide antibody in patients with rheumatoid arthritis. J Rheumatol 30:1451-1455.